Determination the therapeutic effect of Ivermectin and Sovodak on patients infected with COVID-19

Phase 2

Recruiting

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20200408046987N2
• Lead Sponsor: Akam Tejarat Fartak Farasoo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 November 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Patients who test positive for COVID-19 by a commercially available Test
Patients = 20 but < 65 years of age with a temperature (oral) of 38°C and patients 65 - 80 years of age with a temperature (oral) of 37.8°C
Patients with 2 or more of the following symptoms (moderate to severe in intensity) at the time of enrollment:CoughSore throatHeadacheNasal congestionFeeling feverishoBody aches and painsFatigue (tiredness)

Exclusion Criteria

patients with Immuno deficiency
patients under any other antiviral therapy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Chest image(CT scan). Timepoint: at hospital clearance. Method of measurement: Patient's profile(CT scan image).;Hospitalization time. Timepoint: end of intervention. Method of measurement: Hospitalization time.;CBC. Timepoint: Before intervention, 7 days after intervention. Method of measurement: Sampling and lab test.;CRP. Timepoint: Before intervention, 7 days after intervention. Method of measurement: Sampling and lab test.